Recurrent acute liver toxicity from intravenous methyprednisolone;Toxicidad hepática recurrente secundaria a metilprednisolona intravenosa

Revista Espanola de Enfermedades Digestivas

Volumn 100, Issue 11, 2008, Pages 720-723

  Fernández, M Rivero ^a,b   Riesco, J M ^b   Moreira, V F ^a   Moreno, A ^a   Román, A López San ^a   Arranz, G ^a   Del Árbol, L Ruiz ^a  

^a Servicios de Gastroenterología ^*  (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Hepatotoxicity; Methylprednisolone; Multiple sclerosis

Indexed keywords

METHYLPREDNISOLONE;

ACUTE DISEASE; ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; CLINICAL PRACTICE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER INJURY; LIVER TOXICITY; MULTIPLE SCLEROSIS; SIDE EFFECT; BIOPSY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MIDDLE AGED; NECROSIS; PATHOLOGY; RECURRENT DISEASE; REVIEW; TOXIC HEPATITIS;

ACUTE DISEASE; BIOPSY; FEMALE; HEPATITIS, TOXIC; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NECROSIS; RECURRENCE;

EID: 63149133283     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ostapowicz G, Fontana RJ, Schidiot FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54.
2. Lucena, MI, Andrade RJ. Increasing the detection of hepatotoxic response in clinical practice: a quality commitment. Rev Esp Enferm Dig 2005; 97: 145-53.
3. Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega M, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. World J Gas-troenterol 2007; 13: 329-40.
4. Andrade RJ, López-Ortega S. Hepatitis tóxicas. Rev Esp Enferm Dig 2006; 9: 701.
5. Bakke OM, Manocchia M, De Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995; 58:108-17.
6. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
7. Willis C, Maddrey MD. Drug-induced hepatotoxicity. J Clin Gastro-enterol 2005; 39: 83-9.
8. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001; 33: 1009-13.
9. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, Gar-cía-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gas-troenterology 2005; 129: 512-21.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
11. Danan G, Bénichou C. Causality assessment of adverse drug reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
12. María V, Victorino R. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9.
13. Shiota G, Harada K, Oyama K, Udgawa A, Nomi T, Tanaka K, et al. Severe exacerbation of hepatitis alter short-term corticosteroid therapy in a patient with "latent" chronic hepatitis B. Liver 2000; 20: 415-20.
14. Gerolami R, Mambrini P, Barthet M, Jean-Pastor MJ, Salducci J, Gri-maud JC. Acute hepatitis caused by Solupred in a patient with Crohn disease. Gastroenterol Clin Biol 1997; 21: 236-7.
15. Nuñez O, De Andrés C, Álvarez E, García- Monzón C, Clemente G. Hepatitis autoinmune en pacientes con diagnóstico de esclerosis multiple. Gastroenterol Hepatol 2004; 27: 521-4.
16. Iancu TC, Shiloh H, Dembo L. Hepatomegaly following short-term high-dose steroid therapy. J Pediatr Gastroenterol Nutr 1986; 5: 41-6.
17. Nanki T, Koike R, Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol 1999; 94: 3379.
18. Dourakis SP, Sevastionos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolonone therapy. Am J Gastroenterol 2002; 97: 1074-5.
19. Weissel M, Hauff W. Fatal liverfailure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000; 10: 521.
20. Hofstee H, Nannayakkara P, Stehouwer C. Acute hepatitis related to prednisolone. Eur J Int Med 2005; 16: 209-10.
21. Das D, Graham I, Rose J. Recurrent acute hepatitis in patient receiving pulsed methylprednisolone for multiple esclerosis. Indian J Gastroenterol 2006; 25: 314-6.
22. Fernández-Castañer A, García-Cortés M, Lucena MI, Borraz Y, Peláez G, Costa J, et al. Análisis de las causas, características y consecuencias de la reexposición al fármaco o compuesto responsable de un episodio de hepatotoxicidad. Rev Esp Enferm Dig 2008; 100: 278-84.
23. Andrade RJ, Robles M, Ortiz N, Lucena MI. Reexposición en hepatotoxicidad: ¿prueba de concepto o accidente terapéutico? Rev Esp Enferm Dig 2008; 100: 255-8.